2008
DOI: 10.1248/cpb.56.1342
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis and Antibacterial Activity of a New Series of 2,3,5,7-Substituted-pyrido[2,3-d]pyrimidin-4(3H)-one Derivatives

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
4
0

Year Published

2009
2009
2020
2020

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 31 publications
0
4
0
Order By: Relevance
“…All the resultant compounds (288) were examined for antibacterial activity against Gram +ve and Gram −ve bacteria. 280 …”
Section: Orthoester Reactions Under Solvent-free Conditionsmentioning
confidence: 99%
“…All the resultant compounds (288) were examined for antibacterial activity against Gram +ve and Gram −ve bacteria. 280 …”
Section: Orthoester Reactions Under Solvent-free Conditionsmentioning
confidence: 99%
“…The pyridopyrimidine molecule (Figure 1) is a notable pharmacophore in drug design and allied with an extensive range of pharmaceutical properties. The multifaceted synthetic tactics of pyrido[2,3-d]pyrimidine derivatives have expanded noteworthy attention of the medicinal chemists due to its extensive variety of pharmacological applications, namely anticancer agents (Cordeuet al, 2007) (Kansra et al, 2005) anti-diarrhoeal agents (Kots et al, 2008) anti-oxidant agents (Quiroga et al, 2016) antimicrobial activity, (Rashad et al, 2005), (Bheemanapalli et al, 2008), analgesic and anti-inflammatory (Huang et al, 2008) (Lee et al, 2001), anti-proliferative activity (Kalgutkar et al, 2010). Pyrido [2, pyrimidine derivativesalso possessan anti-histaminic activity (Press, 2017), Vistusertib is a novel ATP competitive selective inhibitor of mTOR (Shen et al, 2019).…”
Section: Introductionmentioning
confidence: 99%
“…For example, this heterocyclic structural motif is present in AZD8055 (A), a selective ATP-competitive PI3K-Akt-mTOR signaling pathway inhibitor used for the treatment of antitumor, piritrexim (B), a lipid-soluble inhibitor of dihydrofolate reductase (DHFR) that displays high potency for the treatment of metastatic urothelial cancer, and pyrido[2,3- d ]pyrimidine derivative C that is a hepatitis C virus replicon inhibitor (Figure ). Also, substances that possess the pyrido[2,3- d ]pyrimidine framework have other interesting biological properties such as anticardiovascular, anti-inflammatory, antibacterial, , and anti-Parkinson’s activities . The few methods thus far devised to prepare these substances involve condensation reactions of pyridine or pyrimidine (Scheme ), which are only applied with difficulty when diversified substitution patterns are required.…”
mentioning
confidence: 99%